Compare · EDSA vs SQZ
EDSA vs SQZ
Side-by-side comparison of Edesa Biotech Inc. (EDSA) and SQZ Biotechnologies Company (SQZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. EDSA focuses on Biotechnology: Pharmaceutical Preparations, while SQZ focuses on Medicinal Chemicals and Botanical Products .
- SQZ is the larger of the two at $185.8M, about 3.9x EDSA ($47.7M).
- EDSA has hit the wire 15 times in the past 4 weeks while SQZ has been quiet.
- EDSA has more recent analyst coverage (1 ratings vs 0 for SQZ).
- Company
- Edesa Biotech Inc.
- SQZ Biotechnologies Company
- Price
- $5.30-4.24%
- $0.44+59.83%
- Market cap
- $47.7M
- $185.8M
- 1M return
- -69.25%
- -
- 1Y return
- +189.89%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 15
- 0
- Recent ratings
- 1
- 0
Edesa Biotech Inc.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Latest EDSA
- Edesa Biotech Inc. filed SEC Form 8-K: Other Events
- Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
- Chief Executive Officer Nijhawan Pardeep was granted 1,671 shares, increasing direct ownership by 0.23% to 731,134 units (SEC Form 4)
- Director Marshall Patrick was granted 19,000 shares, increasing direct ownership by 36% to 71,666 units (SEC Form 4)
- Director Macdonald Sean Arthur was granted 19,000 shares, increasing direct ownership by 86% to 41,054 units (SEC Form 4)
- Director Chypyha Joan was granted 19,000 shares, increasing direct ownership by 172% to 30,029 units (SEC Form 4)
- Chief Financial Officer Weiler Peter J. was granted 64,609 shares, increasing direct ownership by 99% to 129,609 units (SEC Form 4)
- President Brooks Michael J was granted 64,609 shares, increasing direct ownership by 28% to 291,479 units (SEC Form 4)
- Director Sistilli Carlo was granted 19,000 shares, increasing direct ownership by 62% to 49,417 units (SEC Form 4)
- Director Olson Charles V was granted 19,000 shares, increasing direct ownership by 173% to 30,000 units (SEC Form 4)
Latest SQZ
- SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)
- SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)
- SEC Form DEFM14A filed by SQZ Biotechnologies Company
- SEC Form PREM14A filed by SQZ Biotechnologies Company
- SEC Form 15-12G filed by SQZ Biotechnologies Company
- SQZ Biotechnologies Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form EFFECT filed by SQZ Biotechnologies Company
- SEC Form POS AM filed by SQZ Biotechnologies Company
- SEC Form S-8 POS filed by SQZ Biotechnologies Company
- SEC Form 10-Q filed by SQZ Biotechnologies Company